Gregory Renza
Stock Analyst at RBC Capital
(2.24)
# 2,691
Out of 4,944 analysts
206
Total ratings
35.6%
Success rate
-0.93%
Average return
Main Sectors:
Stocks Rated by Gregory Renza
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CDTX Cidara Therapeutics | Maintains: Outperform | $31 → $35 | $63.25 | -44.66% | 3 | May 23, 2025 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Outperform | $26 | $25.13 | +3.46% | 16 | May 19, 2025 | |
| ADCT ADC Therapeutics | Reiterates: Outperform | $8 | $3.09 | +158.90% | 12 | May 15, 2025 | |
| INO Inovio Pharmaceuticals | Reiterates: Sector Perform | $5 | $1.70 | +194.12% | 11 | May 14, 2025 | |
| EXEL Exelixis | Reiterates: Outperform | $40 | $38.49 | +3.92% | 10 | May 14, 2025 | |
| ONC BeOne Medicines | Maintains: Outperform | $312 → $311 | $307.51 | +1.13% | 2 | May 8, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Outperform | $182 → $172 | $117.12 | +46.86% | 14 | May 7, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Outperform | $35 → $32 | $7.35 | +335.37% | 3 | May 2, 2025 | |
| AMGN Amgen | Maintains: Outperform | $324 → $320 | $289.33 | +10.60% | 17 | May 2, 2025 | |
| CGON CG Oncology | Maintains: Outperform | $66 → $68 | $26.49 | +156.70% | 3 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $15 | $3.81 | +293.70% | 6 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $12.08 | -0.66% | 6 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $8.02 | +74.56% | 10 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $27 | $10.57 | +155.44% | 11 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $61 | $24.42 | +149.80% | 12 | Jan 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $18 | $24.96 | -27.87% | 11 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $48 | $2.97 | +1,516.16% | 4 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $6 → $10 | $2.61 | +283.14% | 6 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $7 → $10 | $3.73 | +168.10% | 1 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $44 → $47 | $18.86 | +149.27% | 11 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $55 → $57 | $36.61 | +55.70% | 6 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $4 | $6.84 | -41.52% | 3 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $110 → $20 | $6.59 | +203.49% | 7 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $34 | $7.72 | +340.41% | 8 | Sep 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $16 | $5.15 | +210.68% | 1 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $2,160 → $180 | $9.08 | +1,883.47% | 4 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $100 → $80 | $1.71 | +4,578.36% | 5 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $105 → $30 | $0.82 | +3,573.77% | 3 | Jun 2, 2020 |
Cidara Therapeutics
May 23, 2025
Maintains: Outperform
Price Target: $31 → $35
Current: $63.25
Upside: -44.66%
ACADIA Pharmaceuticals
May 19, 2025
Reiterates: Outperform
Price Target: $26
Current: $25.13
Upside: +3.46%
ADC Therapeutics
May 15, 2025
Reiterates: Outperform
Price Target: $8
Current: $3.09
Upside: +158.90%
Inovio Pharmaceuticals
May 14, 2025
Reiterates: Sector Perform
Price Target: $5
Current: $1.70
Upside: +194.12%
Exelixis
May 14, 2025
Reiterates: Outperform
Price Target: $40
Current: $38.49
Upside: +3.92%
BeOne Medicines
May 8, 2025
Maintains: Outperform
Price Target: $312 → $311
Current: $307.51
Upside: +1.13%
Jazz Pharmaceuticals
May 7, 2025
Maintains: Outperform
Price Target: $182 → $172
Current: $117.12
Upside: +46.86%
Bicycle Therapeutics
May 2, 2025
Maintains: Outperform
Price Target: $35 → $32
Current: $7.35
Upside: +335.37%
Amgen
May 2, 2025
Maintains: Outperform
Price Target: $324 → $320
Current: $289.33
Upside: +10.60%
CG Oncology
Apr 29, 2025
Maintains: Outperform
Price Target: $66 → $68
Current: $26.49
Upside: +156.70%
Mar 27, 2025
Maintains: Outperform
Price Target: $16 → $15
Current: $3.81
Upside: +293.70%
Mar 26, 2025
Reiterates: Outperform
Price Target: $12
Current: $12.08
Upside: -0.66%
Mar 21, 2025
Maintains: Outperform
Price Target: $16 → $14
Current: $8.02
Upside: +74.56%
Jan 29, 2025
Maintains: Outperform
Price Target: $26 → $27
Current: $10.57
Upside: +155.44%
Jan 15, 2025
Reiterates: Outperform
Price Target: $61
Current: $24.42
Upside: +149.80%
Jan 14, 2025
Reiterates: Sector Perform
Price Target: $18
Current: $24.96
Upside: -27.87%
Jan 9, 2025
Maintains: Outperform
Price Target: $68 → $48
Current: $2.97
Upside: +1,516.16%
Jan 7, 2025
Reiterates: Outperform
Price Target: $6 → $10
Current: $2.61
Upside: +283.14%
Dec 19, 2024
Upgrades: Outperform
Price Target: $7 → $10
Current: $3.73
Upside: +168.10%
Dec 17, 2024
Maintains: Outperform
Price Target: $44 → $47
Current: $18.86
Upside: +149.27%
Dec 10, 2024
Maintains: Outperform
Price Target: $55 → $57
Current: $36.61
Upside: +55.70%
Nov 14, 2024
Reiterates: Sector Perform
Price Target: $4
Current: $6.84
Upside: -41.52%
Nov 5, 2024
Downgrades: Sector Perform
Price Target: $110 → $20
Current: $6.59
Upside: +203.49%
Sep 26, 2024
Maintains: Outperform
Price Target: $31 → $34
Current: $7.72
Upside: +340.41%
Aug 14, 2024
Reiterates: Outperform
Price Target: $16
Current: $5.15
Upside: +210.68%
Jun 27, 2023
Downgrades: Sector Perform
Price Target: $2,160 → $180
Current: $9.08
Upside: +1,883.47%
Mar 16, 2022
Maintains: Sector Perform
Price Target: $100 → $80
Current: $1.71
Upside: +4,578.36%
Jun 2, 2020
Downgrades: Sector Perform
Price Target: $105 → $30
Current: $0.82
Upside: +3,573.77%